文献速递慢性肾脏病

进行性肾衰竭高胆固醇血症与肝脏硫酸类肝素-PCSK9相互作用改变相关

Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
PubMed 文献 · J Am Soc Nephrol · 2021-03-23

该研究在单肾切除及衰老诱导的Wistar大鼠CKD模型和高血压MWF大鼠CKD模型中,发现48周龄CKD大鼠出现蛋白尿、血肌酐升高和高胆固醇血症,肝脏PCSK9表达增加且呈异常正弦样分布,硫酸类肝素(HS)链延长,VLDL与CKD肝脏HS结合减少。结论认为进行性CKD诱导肝脏HS延长,增强其与PCSK9的相互作用,可能减少肝脏脂蛋白摄取从而引起血脂异常。

要点

  • CKD大鼠肝脏HS链延长,PCSK9与HS结合增强。
  • CKD时VLDL与肝脏HS结合减少,可能促进高胆固醇血症。
  • PCSK9/HS相互作用或为控制CKD血脂异常的新靶点。

核心结论

  • 进行性CKD诱导肝脏HS延长,增强PCSK9与HS相互作用,可能减少肝脏脂蛋白摄取并导致血脂异常。
  • PCSK9/HS可能成为控制CKD血脂异常的新靶点。

研究设计与样本

  • 在正常血压Wistar大鼠行单肾切除及衰老诱导CKD,并与高血压Munich-Wistar-Frömter(MWF)大鼠CKD模型比较。
  • 比较22周龄与48周龄性别及品系匹配大鼠的指标。

主要发现

  • 48周龄单肾切除Wistar-CKD和MWF-CKD大鼠出现蛋白尿、血肌酐升高和高胆固醇血症(均P<0.05),以高血压MWF-CKD大鼠最明显。
  • 两个CKD组肝脏PCSK9表达均增加(P<0.05),呈异常正弦样定位,22周龄大鼠未见。
  • HS二糖分析、抗HS单克隆抗体染色及HS聚合酶exostosin-1(Ext-1)mRNA表达显示两个CKD组HS链延长。
  • 固相竞争实验显示PCSK9与肝素-白蛋白(HS蛋白多糖类似物)的相互作用关键依赖于多糖链长度。
  • CKD肝脏HS与VLDL结合减少(P<0.05);蛋白尿和血肌酐与血浆胆固醇、PCSK9及HS变化强相关。

临床怎么用

  • 提示CKD血脂异常可能部分源于肝脏HS-PCSK9相互作用改变,为PCSK9/HS靶点干预提供实验依据。

局限性

  • 研究为大鼠模型,结论外推至人类CKD患者需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dyslipidemia is an important risk factor in CKD. The liver clears triglyceride-rich lipoproteins (TRL) via LDL receptor (LDLR), LDLR-related protein-1 (LRP-1), and heparan sulfate proteoglycans (HSPGs), mostly syndecan-1. HSPGs also facilitate LDLR degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9). Progressive renal failure affects the structure and activity of hepatic lipoprotein receptors, PCSK9, and plasma cholesterol. METHODS: Uninephrectomy- and aging-induced CKD in normotensive Wistar rats and hypertensive Munich-Wistar-Frömter (MWF) rats. RESULTS: Compared with 22-week-old sex- and strain-matched rats, 48-week-old uninephrectomized Wistar-CKD and MWF-CKD rats showed proteinuria, increased plasma creatinine, and hypercholesterolemia (all P<0.05), which were most apparent in hypertensive MWF-CKD rats. Hepatic PCSK9 expression increased in both CKD groups (P<0.05), with unusual sinusoidal localization, which was not seen in 22-week-old rats. Heparan sulfate (HS) disaccharide analysis, staining with anti-HS mAbs, and mRNA expression of HS polymerase exostosin-1 (Ext-1), revealed elongated HS chains in both CKD groups. Solid-phase competition assays showed that the PCSK9 interaction with heparin-albumin (HS-proteoglycan analogue) was critically dependent on polysaccharide chain length. VLDL binding to HS from CKD livers was reduced (P<0.05). Proteinuria and plasma creatinine strongly associated with plasma cholesterol, PCSK9, and HS changes. CONCLUSIONS: Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Shrestha P, Adepu S, Vivès RR, et al. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction. J Am Soc Nephrol. 2021. PMID: 33758009. doi:10.1681/ASN.2020091376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。